慢病毒载体感染成年食蟹猴骨髓间充质干细胞

骨髓间充质干细胞(Mesenchymal stem cells,MSCs)具有增殖和多向分化潜能,临床应用广泛,近年来备受关注。另一方面,MSCs易于转导和表达外源基因,是理想的基因工程细胞。非人灵长类(NHPs)和人类具有非常相近的遗传背景,NHPs模型在评价药物疗效和移植治疗等方面具有不可替代的价值。本研究采用密度梯度离心法分离成年食蟹猴骨髓单核细胞(Marrow mononuclear cells,MNCs),贴壁培养MSCs。同时构建表达绿色荧光蛋白(Green fluorescent protein,GFP)的慢病毒载体,感染成年食蟹猴MSCs。结果显示,体外培养的成年食蟹猴MSCs均感染猴泡沫病毒(Simian foamy virus,SFV),体外培养成年食蟹猴MSCs必须添加抗病毒药物Tenofovir。但由于食蟹猴MSCs感染SFV,以及培养中添加了抗病毒药物Tenofovir,慢病毒载体的感染效率明显降低(10%)。本研究通过停用抗病毒药,在细胞复苏后6d转染慢病毒,可大幅提高慢病毒的感染效率(50%)。为成年食蟹猴MSCs作为基因工程细胞应用于实验和临床研究提供了技术保证。     

含GDNF基因的慢病毒载体的构建和其在人胚胎神经干细胞中的表达

利用含胶质源性神经营养因子(Glial cell derived neurotrophic factor, GDNF)基因的慢病毒(Lentivirus)载体转染了人胚胎来源的神经干细胞, 探讨了转染后GDNF在神经干细胞中的体外表达水平及其影响因素。首先GDNF基因被克隆入慢病毒载体, 通过瞬时转染法包装出病毒上清, 经滴度鉴定后分别按拷贝数分别为 1、2.5、5、10转染神经干细胞。转染后细胞经过潮霉素筛选得到均一表达GDNF的神经干细胞体系。其后分别利用酶联免疫吸附(ELISA)方法和Real-time PCR方法测定不同转染组细胞在不同时间点GDNF的蛋白分泌水平和基因表达水平。实验中构建了表达GDNF基因的慢病毒载体, 包装出的病毒上清在体外培养条件下成功转染了神经干细胞, 经潮霉素筛选可以得到均一的持续表达分泌GDNF的人胚胎皮层神经干细胞体系。实验结果表明转染拷贝数可以影响GDNF的分泌水平, 相同条件下转染拷贝数越高, GDNF分泌量越多, 其基因表达水平越高。因此, 含GDNF的慢病毒载体可以成功转染人胚胎来源的神经干细胞, 使其持续表达GDNF, 转染过程中可以通过拷贝数在一定水平上控制GDNF的蛋白分泌水平和基因表达水平。     

小鼠Smad6基因RNAi慢病毒载体的构建与鉴定

构建小鼠Smad6基因RNA干扰（RNAi）慢病毒载体,有效沉默骨髓树突状细胞（BMDC）的Smad6基因表达,为构建骨髓致耐受DC用于哮喘等自身免疫疾病的研究。设计小鼠Smad6 shRNA序列,合成、退火,得到双链DNA,与经酶切后的Psih1-H1-copGFP shRNA Vector载体连接产生LV-shSmad6慢病毒载体,并测序鉴定。转染293TN细胞,包装产生慢病毒,测定滴度。感染小鼠骨髓树突细胞,检测Smad6基因的表达状况成功构建Smad6 shRNA的慢病毒载体LV-shSmad6。包装慢病毒,并显著抑制Smad6 mRNA水平及蛋白水平的表达。成功构建出小鼠Smad6基因shR-NA慢病毒载体,为后期研究Smad6基因在哮喘发病机制及新治疗方法提供了稳定的转染细胞载体。     

促红细胞生成素基因修饰的胎肝基质细胞促进脐血CD34 +细胞向红系分化

通过重组慢病毒系统感染人胎肝基质细胞(fetal liver stromal cells,FLSCs),建立了能够稳定高效表达促红细胞生成素(erythropoietin,EPO)的细胞株EPO/FLSCs.从胎儿肝脏克隆EPO基因,构建重组慢病毒EPO的表达载体,感染FLSCs,根据荧光表达强弱进行流式分选,获得能够继续稳定传代的高表达EPO基因的FLSCs,RT-PCR和ELISA结果证实,细胞株中的EPO基因稳定表达.RT-PCR结果显示,FLSCs的EPO在mRNA水平的表达分别是未转染FLSCs和转染空载体FLSCs的5.63倍和5.71倍.ELISA法检测了转染重组慢病毒EPO表达载体的FLSCs EPO蛋白表达水平,结果显示EPO蛋白的表达水平也明显升高.收集EPO/FLSCs的条件培养基,体外诱导脐血CD34+细胞向造血细胞分化,结果显示向红系定向分化的细胞比例明显居多,有可能为临床细胞治疗提供稳定、高质量的细胞来源.     

小鼠RNA干扰基因RelA慢病毒载体的构建与鉴定

目的：构建小鼠RelA 基因的RNA 干扰慢病毒载体,转染小鼠成骨样细胞并鉴定。方法：针对小鼠RelA 基因序列,设计特异 性的shRNA 序列,应用基因重组技术插入慢病毒载体GV-248。得到的重组质粒转化感受态大肠杆菌DH5-alpha,筛选得到阳性克隆 并扩大培养。所得质粒进行测序分析确定载体构建成功。重组质粒载体及包装辅助质粒转染293T 细胞,得到目的病毒并测定相 应病毒滴度。慢病毒转染MC3T3-E1 细胞后,Real-time PCR 及Western blot 检测MC3T3-E1 细胞RelA 基因及成骨相关基因 ALP、OCN、RANKL的表达。结果：成功构建小鼠RelA 基因的RNA干扰慢病毒载体,感染MC3T3-E1 细胞后,RelA 基因的表达 明显受到抑制,同时RANKL基因表达水平明显下降,ALP、OCN基因表达水平明显上升。结论：成功构建了小鼠RelA 基因的 RNA 干扰慢病毒载体。当小鼠成骨细胞RelA基因表达被干扰,NF-资B 通路被抑制后,小鼠成骨细胞成骨相关基因ALP、OCN的 表达明显上升,成骨功能增强;同时RANKL 的表达明显下降,其介导的破骨细胞骨吸收功能减弱。     

GDF5基因真核表达载体的构建及其在恒河猴骨髓间充质干细胞中的表达

目的克隆人软骨组织生长分化因子5（GDF5）基因及构建GDF5基因真核表达载体,观察其在恒河猴骨髓间充质干细胞（MSCs）中的表达情况。方法采用反转录聚合酶链式反应（RT-PCR）从人胎儿软骨组织克隆hGDF5基因全长cDNA,插入pEGFP-C2载体,构建重组真核表达质粒pEGFP-C2-GDF5。重组质粒脂质体介导法转染MSCs细胞,荧光显微镜观察报告基因的表达,RT-PCR法检测目的基因表达。结果成功克隆人软骨组织GDF5基因和构建GDF5真核表达质粒pEGFP-C2-GDF5,克隆在载体上的基因长度为1505bp,包含全部cDNA编码序列1505bp,测序显示与Genbank上的序列一致。重组质粒转染恒河猴MSCs细胞得到表达,绿色荧光蛋白在转染24h后开始表达,72h达高峰,然后表达逐渐减弱。转染后72h可检测到GDF5mRNA表达。结论人GDF5基因在恒河猴MSCs细胞的成功表达为应用恒河猴模型开展基于细胞的基因疗法修复骨和软骨损伤研究奠定了必要基础。     

小鼠RNA干扰RelA基因慢病毒载体的构建与鉴定

目的:构建小鼠Rel A基因的RNA干扰慢病毒载体,转染小鼠成骨样细胞并鉴定。方法:针对小鼠Rel A基因序列,设计特异性的sh RNA序列,应用基因重组技术插入慢病毒载体GV-248。得到的重组质粒转化感受态大肠杆菌DH5α,筛选得到阳性克隆并扩大培养。所得质粒进行测序分析确定载体构建成功。重组质粒载体及包装辅助质粒转染293T细胞,得到目的病毒并测定相应病毒滴度。慢病毒转染MC3T3-E1细胞后,Real-time PCR及Western blot检测MC3T3-E1细胞Rel A基因及成骨相关基因ALP、OCN、RANKL的表达。结果:成功构建小鼠Rel A基因的RNA干扰慢病毒载体,感染MC3T3-E1细胞后,Rel A基因的表达明显受到抑制,同时RANKL基因表达水平明显下降,ALP、OCN基因表达水平明显上升。结论:成功构建了小鼠Rel A基因的RNA干扰慢病毒载体。当小鼠成骨细胞Rel A基因表达被干扰,NF-κB通路被抑制后,小鼠成骨细胞成骨相关基因ALP、OCN的表达明显上升,成骨功能增强;同时RANKL的表达明显下降,其介导的破骨细胞骨吸收功能减弱。     

体外传代对版纳微型猪骨髓间充质干细胞绿色荧光蛋白表达的影响

目的通过分离扩增版纳微型猪骨髓间充质干细胞(BMSCs)观察传代对慢病毒转染的绿色荧光蛋白(GFP)表达的影响。方法采集4月龄版纳微型猪的骨髓,在DMEM/F12培养液中分离间充质干细胞(MSCs),并根据其形态学、抗原标志表达和分化潜能给予鉴定。MSCs与GFP慢病毒载体共培养,荧光显微镜观察GFP的表达,流式细胞仪检测传代后MSCs GFP表达率的变化。标记后传代至1、2、3、4代细胞间比较用非参数检验。结果采用直接培养骨髓,可以分离到高表达CD13、CD29、CD90、CD105的MSCs,并可诱导分化为脂肪、骨和软骨细胞。MSCs与携带GFP的慢病毒载体共培养3天即可观察到GFP的表达,最佳转染复数(MOI)值为50,最佳共培养时间为6 d。传代后MSCs GFP表达率呈下降趋势[1代转染率(42.3±2.25)%、2代转染率(41.6±2.65)%、3代转染率(41.4±3.75)%和4代转染率(38.2±4.75)%],但传至4代GFP表达率的变化差异无统计学意义(P0.05)。结论采用含有10%胎牛血清的DMEM/F12培养液可以从版纳微型猪骨髓中分离到MSCs,GFP慢病毒转染是标记MSCs的有效方法,连续传代4代不会显著影响GFP的表达。     

用慢病毒转染RNAi技术沉默胆固醇7α羟化酶的基因表达，降低肝细胞中胆汁酸的分泌

为了降低生物人工肝(bioartificial liver system)中肝细胞胆汁酸的分泌,构建了胆固醇7α羟化酶慢病毒RNA干涉载体,并转染人肝脏细胞(L-02).根据绿色荧光蛋白的表达评估转染效率后进行流式分选,获得高表达慢病毒干涉载体的细胞,并以野生型L-02细胞和仅转染pSicoR空载体的L-02细胞作对照,观察肝细胞胆固醇7α羟化酶的表达以及培养上清中总胆汁酸含量.利用半定量PCR、实时荧光定量PCR及Western-blot等实验方法检测了转染细胞中基因的干涉效果,结果显示:与对照组相比,在mRNA水平,转染慢病毒siRNA载体的L-02细胞,其胆固醇7α羟化酶基因的表达量仅为野生型L-02细胞表达量的31.2%,为转染pSicoR空载体的L-02细胞的34.1%,干涉效率分别为68.8%和65.9%,均具有显著差异(P＜0.05);Western-blot结果显示胆固醇7α羟化酶在蛋白质水平表达也明显受到抑制,表明转染慢病毒siRNA下调了肝细胞中胆固醇7α羟化酶基因的表达,减少了胆汁酸的分泌.以上研究结果表明,利用RNAi技术可以获得低表达胆固醇7α羟化酶基因的肝细胞,并有效降低肝细胞中胆汁酸的分泌,为临床上生物人工肝的构建及应用奠定基础.     

gas6基因修饰小鼠骨髓间充质干细胞的构建及鉴定

目的:制备携带生长停滞特异性基因6(gas6)的慢病毒,并构建和鉴定稳定表达生长停滞特异性蛋白6(GAS6)的小鼠骨髓间充质干细胞(MSCs)。方法:采用全骨髓贴壁法分离培养MSCs,用流式细胞术检测MSCs标志分子;根据Gen Bank中小鼠gas6基因序列设计并合成上下游引物,以MSCs提取的m RNA制备的c DNA为模板扩增gas6基因片段,克隆入慢病毒表达载体,获得Lenti-gas6-GFP-zeocin质粒并测序鉴定;采用三质粒包装系统(穿梭质粒p Lenti-gas6-GZ、包装质粒p SPAX2和p MD2.G)包装慢病毒,并验证其表达目的基因情况;将浓缩的慢病毒离心感染第4代MSCs,用吉欧霉素(zeocin)筛选培养后获得稳定表达GAS6的MSCs,采用流式细胞术检测其阳性率以及表面标志分子表达情况。结果:构建了携带gas6基因的慢病毒,建立了gas6基因修饰的MSCs。结论:慢病毒载体可介导gas6基因在小鼠MSCs中过表达,且不会干扰MSCs的生物特性,为进一步研究gas6基因修饰的MSCs的治疗作用奠定了实验基础。     

Infusion of mesenchymal stem cells overexpressing GDNF ameliorates renal function in nephrotoxic serum nephritis

Nephrotoxic serum nephritis (NSN) is a well-established animal model of glomerulonephritis, a frequent clinical condition with a high mortality rate owing to the ineffectiveness of current therapies. Mesenchymal stem cells (MSCs) are adult stem cells with potential as novel therapies in regenerative medicine owing to the absence of allogenic rejection. Glial cell-derived neurotrophic factor (GDNF) acts as a morphogen in kidney development. The therapeutic effectiveness of bone marrow MSCs overexpressing GDNF (GDNF-MSCs) was evaluated in an NSN rat model. An adenoviral vector was used to transduce MSCs with GDNF and a green fluorescent protein reporter gene. Then, GDNF-MSCs were injected into NSN rats via the renal artery. The influence of GDNF on renal injury was assessed. The location of GDNF-MSCs in kidneys was detected using fluorescence microscopy, cells were counted, and kidney function was measured. Infusion of GNDF-MSCs enhanced the recovery of renal function in NSN rats. MSCs were detected in the kidney cortex after injection. Compared with control MSCs, GDNF-MSCs led to significantly better renal function and injury recovery in NSN rats. GDNF has a positive effect on MSC differentiation in renal tissue. Owing to their highly renoprotective capacity, GDNF-MSCs represent a possible novel cell-based paradigm for treatment of glomerulonephritis.     

Generation of functional neutrophils from a mouse model of X-linked chronic granulomatous disorder using induced pluripotent stem cells

Murine models of human genetic disorders provide a valuable tool for investigating the scope for application of induced pluripotent stem cells (iPSC). Here we present a proof-of-concept study to demonstrate generation of iPSC from a mouse model of X-linked chronic granulomatous disease (X-CGD), and their successful differentiation into haematopoietic progenitors of the myeloid lineage. We further demonstrate that additive gene transfer using lentiviral vectors encoding gp91(phox) is capable of restoring NADPH-oxidase activity in mature neutrophils derived from X-CGD iPSC. In the longer term, correction of iPSC from human patients with CGD has therapeutic potential not only through generation of transplantable haematopoietic stem cells, but also through production of large numbers of autologous functional neutrophils.     

Overexpression of HIF-1α in mesenchymal stem cells contributes to repairing hypoxic-ischemic brain damage in rats

Preclinical researches on mesenchymal stem cells (MSCs) transplantation, which is used to treat hypoxic-ischemic (HI) brain damage, have received inspiring achievements. However, the insufficient migration of active cells to damaged tissues has limited their potential therapeutic effects. There are some evidences that hypoxia inducible factor-1 alpha (HIF-1α) promotes the viability and migration of the cells. Here, we aim to investigate whether overexpression of HIF-1α in MSCs could improve the viability and migration capacity of cells, and its therapeutic efficiency on HI brain damage. In the study, MSCs with HIF-1α overexpression was achieved by recombinant lentiviral vector and transplanted to the rats subsequent to HI. Our data indicated that overexpression of HIF-1α promoted the viability and migration of MSCs, HIF-1α overexpressed MSCs also had a stronger therapeutic efficiency on HI brain damaged treatment by mitigating the injury on behavioral and histological changes evoked by HI insults, accompanied with more MSCs migrating to cerebral damaged area. This study demonstrated that HIF-1α overexpression could increase the MSCs’ therapeutic efficiency in HI and the promotion of the cells’ directional migration to cerebral HI area by overexpression may be responsible for it, which showed that transplantation of MSCs with HIF-1α overexpression is an attractive therapeutic option to treat HI-induced brain injury in the future.     

MicroRNA-377 Regulates Mesenchymal Stem Cell-Induced Angiogenesis in Ischemic Hearts by Targeting VEGF

MicroRNAs have been appreciated in various cellular functions, including the regulation of angiogenesis. Mesenchymal-stem-cells (MSCs) transplanted to the MI heart improve cardiac function through paracrine-mediated angiogenesis. However, whether microRNAs regulate MSC induced angiogenesis remains to be clarified. Using microRNA microarray analysis, we identified a microRNA expression profile in hypoxia-treated MSCs and observed that among all dysregulated microRNAs, microRNA-377 was decreased the most significantly. We also validated that vascular endothelial growth factor (VEGF) is a target of microRNA-377 using dual-luciferase reporter assay and Western-blotting. Knockdown of endogenous microRNA-377 promoted tube formation in human umbilical vein endothelial cells. We then engineered rat MSCs with lentiviral vectors to either overexpress microRNA-377 (MSC^miR-377) or knockdown microRNA-377 (MSC^Anti-377) to investigate whether microRNA-377 regulated MSC-induced myocardial angiogenesis, using MSCs infected with lentiviral empty vector to serve as controls (MSC^Null). Four weeks after implantation of the microRNA-engineered MSCs into the infarcted rat hearts, the vessel density was significantly increased in MSC^Anti-377-hearts, and this was accompanied by reduced fibrosis and improved myocardial function as compared to controls. Adverse effects were observed in MSC^miR-377-treated hearts, including reduced vessel density, impaired myocardial function, and increased fibrosis in comparison with MSC^Null-group. These findings indicate that hypoxia-responsive microRNA-377 directly targets VEGF in MSCs, and knockdown of endogenous microRNA-377 promotes MSC-induced angiogenesis in the infarcted myocardium. Thus, microRNA-377 may serve as a novel therapeutic target for stem cell-based treatment of ischemic heart disease.     

Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination

Mesenchymal stem/stromal cells (MSCs) can be isolated from most adult tissues and hold considerable promise for tissue regenerative therapies. Some of the potential advantages that MSCs have over other adult stem cell types include: (1) their relative ease of isolation, culture and expansion; (2) their immunomodulatory properties; (3) they can provide trophic support to injured tissues; (4) they can be transduced by retroviral vectors at a high efficiency; (5) they have an ability to home to sites of inflammation and injury. Collectively these characteristics suggest that MSCs are attractive vehicles for cell and gene therapy applications. In the current study, we investigated whether transplantation of human adipose-derived MSCs (Ad-MSCs) engineered to overexpress the anti-inflammatory cytokine interleukin (IL)-4 was efficacious in experimental autoimmune encephalomyelitis (EAE). Ad-MSCs transduced with a bicistronic lentiviral vector encoding mouse IL-4 and enhanced green fluorescent protein (Ad-IL4-MSCs) stably expressed, relatively high levels of both transgenes. Importantly the phenotypic and functional attributes of Ad-IL4-MSCs, such as the expression of homing molecules and differentiation capacity, was not altered by the transduction process. Notably, the early administration of Ad-IL4-MSCs in mice with EAE at the time of T-cell priming attenuated clinical disease. This protective effect was associated with a reduction in peripheral MOG-specific T-cell responses and a shift from a pro- to an anti-inflammatory cytokine response. These data suggest that the delivery of Ad-MSCs genetically engineered to express anti-inflammatory cytokines may provide a rational approach to promote immunomodulation and tissue protection in a number of inflammatory and degenerative diseases including multiple sclerosis.     

Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination

Mesenchymal stem/stromal cells (MSCs) can be isolated from most adult tissues and hold considerable promise for tissue regenerative therapies. Some of the potential advantages that MSCs have over other adult stem cell types include: (1) their relative ease of isolation, culture and expansion; (2) their immunomodulatory properties; (3) they can provide trophic support to injured tissues; (4) they can be transduced by retroviral vectors at a high efficiency; (5) they have an ability to home to sites of inflammation and injury. Collectively these characteristics suggest that MSCs are attractive vehicles for cell and gene therapy applications. In the current study, we investigated whether transplantation of human adipose-derived MSCs (Ad-MSCs) engineered to overexpress the anti-inflammatory cytokine interleukin (IL)-4 was efficacious in experimental autoimmune encephalomyelitis (EAE). Ad-MSCs transduced with a bicistronic lentiviral vector encoding mouse IL-4 and enhanced green fluorescent protein (Ad-IL4-MSCs) stably expressed, relatively high levels of both transgenes. Importantly the phenotypic and functional attributes of Ad-IL4-MSCs, such as the expression of homing molecules and differentiation capacity, was not altered by the transduction process. Notably, the early administration of Ad-IL4-MSCs in mice with EAE at the time of T-cell priming attenuated clinical disease. This protective effect was associated with a reduction in peripheral MOG-specific T-cell responses and a shift from a pro- to an anti-inflammatory cytokine response. These data suggest that the delivery of Ad-MSCs genetically engineered to express anti-inflammatory cytokines may provide a rational approach to promote immunomodulation and tissue protection in a number of inflammatory and degenerative diseases including multiple sclerosis.     

microRNA499 慢病毒载体转染诱导大鼠骨髓间充质干细胞 向心肌样细胞分化*

目的:探讨microRNA 499(miR-499)慢病毒转染对诱导大鼠骨髓来源间充质干细胞(BM-MSCs)向心肌样细胞分化的作用。方法:取第四代Wistar大鼠骨髓来源间充质干细胞进行流式细胞检测,鉴定干细胞表面特异标记物。使用符合干细胞鉴定标准的细胞批次用于后续实验。实验设置miR499慢病毒转染、慢病毒空白转染2个处理组,分别于处理后即日、1d,3d,5d,7d收集细胞进行下列实验:实时荧光定量PCR检测心肌重要转录因子GATA4、NKx2.5和MEF2C的mRNA表达,western-blot检测心肌特异蛋白I(cTnI)的表达。结果:培养第四代Wistar大鼠骨髓来源间充质干细胞表达干细胞表面特异标记物,可用于实验。大鼠骨髓来源间充质干细胞microRNA 499慢病毒载体转染后microRNA 499表达明显升高,且转染后1d,3d,5d,7d,GATA4、NKx2.5和MEF2C的mRNA表达逐渐增强。慢病毒空白转染组未见明显变化。western-blot检测自第3天开始可见cTnI阳性表达条带,慢病毒空白转染组未检测到明显阳性表达条带。结论:microRNA 499可诱导大鼠骨髓来源间充质干细胞向心肌样细胞分化。